Coloplast (Denmark) Performance
| COLO-B Stock | DKK 894.20 3.60 0.40% |
The firm shows a Beta (market volatility) of 0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Coloplast's returns are expected to increase less than the market. However, during the bear market, the loss of holding Coloplast is expected to be smaller as well. At this point, Coloplast AS has a negative expected return of -0.0129%. Please make sure to confirm Coloplast's treynor ratio, value at risk, and the relationship between the total risk alpha and maximum drawdown , to decide if Coloplast AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Coloplast AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong essential indicators, Coloplast is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 448 M | |
| Total Cashflows From Investing Activities | -11.8 B |
Coloplast |
Coloplast Relative Risk vs. Return Landscape
If you would invest 90,460 in Coloplast AS on August 28, 2024 and sell it today you would lose (1,400) from holding Coloplast AS or give up 1.55% of portfolio value over 90 days. Coloplast AS is generating negative expected returns and assumes 1.5002% volatility on return distribution over the 90 days horizon. Simply put, 13% of stocks are less volatile than Coloplast, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Coloplast Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Coloplast's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Coloplast AS, and traders can use it to determine the average amount a Coloplast's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0086
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | COLO-B |
Estimated Market Risk
| 1.5 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Coloplast is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Coloplast by adding Coloplast to a well-diversified portfolio.
Coloplast Fundamentals Growth
Coloplast Stock prices reflect investors' perceptions of the future prospects and financial health of Coloplast, and Coloplast fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Coloplast Stock performance.
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 203.46 B | |||
| Shares Outstanding | 194.31 M | |||
| Price To Earning | 42.10 X | |||
| Price To Book | 22.36 X | |||
| Price To Sales | 7.79 X | |||
| Revenue | 22.58 B | |||
| EBITDA | 7.23 B | |||
| Cash And Equivalents | 620 M | |||
| Cash Per Share | 2.92 X | |||
| Total Debt | 16.36 B | |||
| Debt To Equity | 43.40 % | |||
| Book Value Per Share | 27.81 X | |||
| Cash Flow From Operations | 5.1 B | |||
| Earnings Per Share | 21.76 X | |||
| Total Asset | 34.96 B | |||
| Retained Earnings | 4.7 B | |||
| Current Asset | 6.01 B | |||
| Current Liabilities | 4.78 B | |||
About Coloplast Performance
By analyzing Coloplast's fundamental ratios, stakeholders can gain valuable insights into Coloplast's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Coloplast has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Coloplast has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Coloplast AS develops and markets intimate healthcare products and services worldwide. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast operates under Healthcare Products classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 12000 people.Things to note about Coloplast AS performance evaluation
Checking the ongoing alerts about Coloplast for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Coloplast AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Coloplast AS generated a negative expected return over the last 90 days | |
| About 35.0% of the company shares are held by company insiders |
- Analyzing Coloplast's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Coloplast's stock is overvalued or undervalued compared to its peers.
- Examining Coloplast's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Coloplast's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Coloplast's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Coloplast's stock. These opinions can provide insight into Coloplast's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Coloplast Stock analysis
When running Coloplast's price analysis, check to measure Coloplast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coloplast is operating at the current time. Most of Coloplast's value examination focuses on studying past and present price action to predict the probability of Coloplast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coloplast's price. Additionally, you may evaluate how the addition of Coloplast to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |